2024 Polish Recommendations for the Management of Familial Hypercholesterolemia in Children and Adolescents.

Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology of Developmental Age, Pomeranian Medical University, Szczecin, Poland, Poland

Department of Pediatrics, Oncology and Pediatric Immunology, Pomeranian Medical University, Szczecin, Poland, Poland

Department of Inborn Errors of Metabolism and Paediatrics, the Institute of Mother and Child, Warsaw, Poland, Poland

Department of Cardiology, Children's Memorial Health Institute, Warsaw, Poland, Poland

1st Department of Cardiology, Medical University of Gdansk, Poland, Poland

Department of Biology and Medical Genetics, Medical University of Gdansk, Gdansk, Poland, Poland

Laboratory of Clinical Genetics, University Clinical Centre, Gdansk, Poland, Poland

Department of Clinical Genetics, Medical University of Lodz, 90-419 Lodz, Poland

Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland, Poland

Ciccarone Center for the Prevention of Cardiovascular Disease, School of Medicine, John Hopkins University, Baltimore, MD, USA, United States

Center for the Atherosclerosis and Cardiovascular Diseases Prevention, Faculty of Medicine, the John Paul II Catholic University of Lublin, Lublin, Poland.

Submission date: 2024-08-24

Final revision date: 2024-11-22

Acceptance date: 2024-11-22

Online publication date: 2024-11-22

Corresponding author

Malgorzata Mysliwiec

Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdansk, Poland, Debinki, 80-211, Gdansk, Poland

DOI: https://doi.org/10.5114/aoms/196329

Article (PDF)

KEYWORDS

familial hypercholesterolemia

atherosclerosis

cardiovascular disease

TOPICS

ABSTRACT

Familial hypercholesterolemia (FH) is the most common monogenic disease leading to the accelerated development of atherosclerotic cardiovascular disease (ASCVD). Despite increasing medical knowledge, diagnostic testing, and a growing number of therapeutic options, the effectiveness of detecting and treating FH remains highly insufficient. Only early detection (as early as possible) and optimal treatment in pediatric patients will lead to a significant reduction in morbidity and mortality from atherosclerotic cardiovascular disease (ASCVD) in later years. We present the guidelines for the management of FH in children and adolescents in Poland. This document is an update of the 2014 Position Paper of the Lipid Expert Forum.

Submit your paper

eISSN:	1896-9151
ISSN:	1734-1922